Home › Compare › PRFUF vs ABBV
PRFUF yields 80000.00% · ABBV yields 3.06%● Live data
📍 PRFUF pulled ahead of the other in Year 1
Combined, PRFUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PRFUF + ABBV for your $10,000?
Prosperous Future Holdings Limited, an investment holding company, manufactures and sells personal care products in the People's Republic of China, Hong Kong, the United States, the United Kingdom, and internationally. It operates through Personal Care Products, Food and Beverage, Financial business, Properties Holding, and Others segments. The company manufactures and sells skin care, body, and hair care products; offers frozen food and beverage products, including meat and poultry; provides frozen warehouse services; and asset management, data analysis, and securities advisory services, as well as deals in securities and futures contracts. In addition, it invests in listed securities and private unlisted funds; offers money lending, finance lease, and factoring services; and provides professional services, such as fund setup and administration, legal and tax consultancy and co-ordination, corporate and accounting, and trust and fiduciary services. Further, the company develops and leases properties; and provides temperature-controlled storage and ancillary services, as well as engages in trading, money lending, and finance lease services. Prosperous Future Holdings Limited was formerly known as Future Development Holdings Limited and changed its name to Prosperous Future Holdings Limited in September 2019. The company was incorporated in 2011 and is headquartered in Central, Hong Kong.
Full PRFUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.